Efficacy and safety of Ginkgo biloba extract EGb 761® in mild cognitive impairment with neuropsychiatric symptoms: A randomized, placebo-controlled, double-blind, multicenter trial

International Journal of Geriatric Psychiatry

Volumn 29, Issue 10, 2014, Pages 1087-1095

  Gavrilova, S I ^a   Preuss, U W ^b   Wong, J W M ^b   Hoerr, R ^c   Kaschel, R ^d   Bachinskaya, N ^e  

^a MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^b Hospital of Prignitz   (Germany)

^c DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^d UNIVERSITY OF OSNABRÜCK   (Germany)

^e INSTITUTE OF GERONTOLOGY   (Ukraine)

Author keywords

Behavior; EGb 761 ; Executive function; Ginkgo biloba; Mild cognitive impairment; Neuropsychiatric symptoms

Indexed keywords

GINKGO BILOBA EXTRACT; GINKGO BILOBA EXTRACT 761; PLANT EXTRACT;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELEVATED BLOOD PRESSURE; EPIGASTRIC DISCOMFORT; EXECUTIVE FUNCTION; FEMALE; GERIATRIC DEPRESSION SCALE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; STATE TRAIT ANXIETY INVENTORY; ANXIETY; CLINICAL TRIAL; DEPRESSIVE DISORDER; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHYTOTHERAPY; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANXIETY; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84908703828     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4103     Document Type: Article

References (55)

1. Abdel-Kader R, Hauptmann S, Keil U, Scherping I, Leuner K, Eckert A, Müller WE. 2007. Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761®). Pharmacol Res 56: 493-502.
2. Ahmed S, Mitchell J, Arnold R, Nestor PJ, Hodges JR. 2008. Predicting rapid clinical progression in amnestic mild cognitive impairment. Dement Geriatr Cogn Disord 25: 170-177.
3. Bachinskaya N, Hoerr R, Ihl R. 2011. Alleviating neuropsychiatric symptoms in dementia: The effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat 7: 209-215.
4. Blacker D, Lee H, Muzikansky A, et al. 2007. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 64: 862-871.
5. Brown PJ, Devenand DP, Liu X, Caccappolo E, for the Alzheimer's Disease Neuroimaging Initiative. 2011. Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch Gen Psychiatry 68: 617-626.
6. Chan DC, Kasper JD, Black BS, Rabins PV. 2003. Prevalence and correlates of behavioral and psychiatric symptoms in community-dwelling elders with dementia or mild cognitive impairment: The Memory and Medical Care Study. Int J Geriatr Psychiatry 18: 174-182.
7. Collie A, Maruff P, Shafiq-Antonacci R, et al. 2001. Memory decline in healthy older people. Implications for identifying mild cognitive impairment. Neurology 56: 1533-1538.
8. Cummings JL. 1997. The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology 48(Suppl 6): S10-S16.
9. Di Iulio F, Palmer K, Blundo C, et al. 2010. Occurrence of neuropsychiatric symptoms and psychiatric disorders in mild Alzheimer's disease and mild cognitive impairment subtypes. Int Psychogeriatr 22: 629-640.
10. Ebly EM, Hogan DB, Parhad IM. 1995. Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol 52: 612-619.
11. Elias MF, Beiser A, Wolf PA, et al. 2000. The preclinical phase of Alzheimer disease. A 22-year prospective study of the Framingham cohort. Arch Neurol 57: 808-813.
12. Erdinçler DS, Karakoç Y, Toplan S, Önen S, Sukyasyan A, Beger T, Demiroglu C. 1996. The effect of Ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability. Clin Hemorheol 16: 271-276.
13. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
14. Forsell Y, Palmer K, Fratiglioni L. 2003. Psychiatric symptoms/syndromes in elderly persons with mild cognitive impairment. Data from a cross-sectional study. Acta Neurol Scand 107(Suppl 179): 25-28.
15. Förstl H, Bickel H, Frölich L, et al. 2008. Mild cognitive impairment with predictors of rapid decline. [Leichte kognitive Beeinträchtigung mit Vorzeichen rascher Verschlechterung]. Dtsch Med Wochenschrift 133: 431-436.
16. Gainotti G, Ferraccioli M, Vita MG, Marra C. 2008. Patterns of neuropsychological impairment in MCI patients with small subcortical infarcts or hippocampal atrophy. J Int Neuropsychol Soc 14: 611-619.
17. Gallagher D, Coen R, Kilroy D, et al. 2011. Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment. Int J Geriatr Psychiatry 26: 166-172.
18. Geda YE, Roberts RO, Knopman DS, et al. 2008. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging. Arch Gen Psychiatry 65: 1193-1198.
19. Grass-Kapanke B, Busmane A, Lasmanis A, Hoerr R, Kaschel R. 2011. Effects of Ginkgo biloba special extract EGb 761® in very mild cognitive impairment (vMCI). Neurosci Med 2: 48-56.
20. Grober E, Hall CB, Lipton RB, et al. 2008. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease. J Int Neuropsychol Soc 14: 166-278.
21. Herrschaft H, Nacu A, Likhachev S, et al. 2012. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res 46: 716-723.
22. Huppert FA, Brayne C, Gill C, Paykel ES, Beardsall L. 1995. CAMCOG-A concise neuropsychological test to assist dementia diagnosis: Sociodemographic determinants in an elderly population sample. Br J Clin Psychol 34: 529-541.
23. ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1996. Good Clinical Practice: Consolidated Guideline. ICH: Geneva.
24. Ihl R, Bachinskaya N, Korczyn AD, et al. 2011. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: A randomized controlled trial. Int J Geriatr Psychiatry 26: 1186-94.
25. Jessen F, Wiese B, Bachmann C, et al. 2010. Prediction of dementia by subjective memory impairment. Effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 67: 414-422.
26. Jorm AF. 1994. A short form for the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Development and cross-validation. Psychol Med 24: 145-153.
27. Kaschel R. 2009. Ginkgo biloba: Specificity of neuropsychological improvement -A selective review in search of differential effects. Hum Psychopharmacol 24: 345-370.
28. Kaschel R. 2011. Specific memory effects of Ginkgo biloba extract EGb 761® in middle-Aged healthy volunteers. Phytomedicine 18: 1202-1207.
29. Kawas CH, Corrada MM, Brookmeyer R, et al. 2003. Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology 60: 1089-1093.
30. Larrieu S, Letenneur L, Orgogozo JM, et al. 2002. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59: 1594-1599.
31. Lyketsos CG, Lopez O, Jones B, et al. 2002. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. Results from the Cardiovascular Health Study. JAMA 288: 1475-1483.
32. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. 1999. The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56: 1388-1393.
33. Morris JC, Storandt M, Miller P, et al. 2001. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58: 397-405.
34. Müller WE, Heiser J, Leuner K. 2012. Effects of the standardized Ginkgo biloba extract EGb 761® on neuroplasticity. Int Psychogeriatr 24(Suppl 1): S21-S24.
35. Nacu A, Hoerr R, Herrschaft H. 2011. Neuropsychiatric symptoms of dementia and related caregiver distress: Effect of treatment by a once-daily formulation of Gingko biloba extract EGb 761. Alzheimers Dement 7(Suppl 1): S782.
36. Napryeyenko O, Borzenko I, for the GINDEM-NP Study Group. 2007. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebocontrolled, double-blind clinical trial. Arzneimittelforschung 56: 4-11.
37. NIMH National Institute of Mental Health. 1976. 028 CGI. Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology, rev. ed, Guy W (ed). NIMH: Rockville; 218-222.
38. Palmer K, Berger AK, Monastero R, et al. 2007. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology 69: 1596-1602.
39. Petersen RC, Smith GE, Waring SC, et al. 1999. Mild cognitive impairment. Clinical characterisation and outcome. Arch Neurol 56: 303-308.
40. Ramakers IHGB, Verhey FRJ, Scheltens P, et al. 2013. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 43: 911-920.
41. Reitan RM. 1958. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8: 271-276.
42. Robert PH, Berr C, Volteau M, et al. 2006. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: A one-year follow-up study. Clin Neurol Neurosurg 108: 733-736.
43. Scripnikov A, Khomenko A, Napryeyenko O, GINDEM-NP Study Group. 2007. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: Findings from a randomised controlled trial. Wien Med Wochenschr 157: 295-300.
44. Sheikh JI, Yesavage JA. 1986. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin Gerontol 5: 165-173.
45. Smith G. 2002. Is mild cognitive impairment bridging the gap between normal aging and Alzheimer's disease? J Neural Transm 62(Suppl): 97-104.
46. Spielberger CD, Gorsuch RL, Lushene RE. 1970. STAI: Manual for the State-Trait Anxiety Inventory. Consulting Psychology Press: Palo Alto.
47. Tchantchou F, Xu Y, Wu Y, Christen Y, Luo Y. 2007. EGb 761® enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J 21: 2400-2408.
48. Teng E, Lu PH, Cummings JL. 2007. Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease. Dement Geriatr Cogn Disord 24: 253-259.
49. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. 2010. Effects of Ginkgo biloba in dementia: Systematic review and meta-Analysis. BMC Geriatr 10: Art 14.
50. Wilson RS, Hoganson GM, Rajan KB, et al. 2010. Temporal course of depressive symptoms during the development of Alzheimer disease. Neurology 75: 21-26.
51. Winblad B, Palmer K, Kivipelto M, et al. 2004. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256: 240-246.
52. Woelk H, Arnoldt KH, Kieser M, Hoerr R. 2007. Ginkgo biloba special extract EGb 761® in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 41: 472-480.
53. Wolf H, Grunwald M, Ecke GM, et al. 1998. The prognosis of mild cognitive impairment in the elderly. J Neural Transm 54(Suppl): 31-50.
54. Yesavage JA, Brink TL, Rose TL, et al. 1983. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17: 37-49.
55. Zaudig M. 2002. Mild cognitive impairment in the elderly. Curr Opin Psychiatry 15: 387-393.